Among the anti-CD22 ADCs (Table 2) [132–140], inotuzumab ozogamicin (CMC-544) was approved by the FDA in August 2017 for R/R B cell ALL as monotherapy and it is also increasingly evaluated in preclinical and clinical trials against lymphoma. The gene discussed is CD22; the disease is lymphoma.